|
ES2032831T5
(es)
|
1986-08-19 |
2001-02-16 |
Genentech Inc |
Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
|
|
JPH01215289A
(ja)
|
1988-02-22 |
1989-08-29 |
Toa Nenryo Kogyo Kk |
遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
|
|
FR2649991B2
(fr)
|
1988-08-05 |
1994-03-04 |
Rhone Poulenc Sante |
Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
|
|
US5728553A
(en)
|
1992-09-23 |
1998-03-17 |
Delta Biotechnology Limited |
High purity albumin and method of producing
|
|
ES2245780T3
(es)
|
1994-05-18 |
2006-01-16 |
Nektar Therapeutics |
Metodos y composiciones para la formulacion de interferones como un polvo seco.
|
|
DE4417598A1
(de)
|
1994-05-19 |
1995-12-14 |
Max Planck Gesellschaft |
Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
|
|
AU5132096A
(en)
|
1995-01-30 |
1996-08-21 |
Terrapin Technologies, Inc. |
Glubodies - multiplicities of proteins capable of binding a variety of small molecules
|
|
US5908621A
(en)
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
|
US6620413B1
(en)
|
1995-12-27 |
2003-09-16 |
Genentech, Inc. |
OB protein-polymer chimeras
|
|
DE19641876B4
(de)
|
1996-10-10 |
2011-09-29 |
Iba Gmbh |
Streptavidinmuteine
|
|
WO1998016873A1
(en)
|
1996-10-14 |
1998-04-23 |
Firm Forsat Ltd. |
Method for preparing dispersions of chromogenic components
|
|
DE19742706B4
(de)
|
1997-09-26 |
2013-07-25 |
Pieris Proteolab Ag |
Lipocalinmuteine
|
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
|
CA2233725A1
(en)
|
1998-03-31 |
1999-09-30 |
Hemosol Inc. |
Hemoglobin-hydroxyethyl starch complexes
|
|
CZ298681B6
(cs)
|
1998-06-08 |
2007-12-19 |
F. Hoffmann-La Roche Ag |
Lécivo pro lécení infekcí chronické hepatitis C
|
|
US6403564B1
(en)
|
1998-10-16 |
2002-06-11 |
Schering Corporation |
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
|
|
DE19926068C1
(de)
|
1999-06-08 |
2001-01-11 |
Arne Skerra |
Muteine des Bilin-Bindungsproteins
|
|
US7211395B2
(en)
|
2001-03-09 |
2007-05-01 |
Dyax Corp. |
Serum albumin binding moieties
|
|
WO2003029462A1
(en)
|
2001-09-27 |
2003-04-10 |
Pieris Proteolab Ag |
Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
|
|
CA2464690A1
(en)
|
2001-09-27 |
2003-04-10 |
Pieris Proteolab Ag |
Muteins of apolipoprotein d
|
|
US7691970B2
(en)
|
2003-08-25 |
2010-04-06 |
Pieris Ag |
Muteins of a bilin-binding protein with affinity for a given target
|
|
WO2005019255A1
(en)
|
2003-08-25 |
2005-03-03 |
Pieris Proteolab Ag |
Muteins of tear lipocalin
|
|
JP2007284351A
(ja)
|
2004-07-27 |
2007-11-01 |
Osaka Bioscience Institute |
アミロイド蛋白質の凝集を抑制する物質とその作用
|
|
WO2006056464A2
(en)
|
2004-11-26 |
2006-06-01 |
Pieris Ag |
Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
|
|
WO2006078717A2
(en)
*
|
2005-01-19 |
2006-07-27 |
Beth Israel Deaconess Medical Center |
Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis
|
|
EP1929073A4
(en)
|
2005-09-27 |
2010-03-10 |
Amunix Inc |
PROTEIN MEDICAMENT AND ITS USE
|
|
CA2702611A1
(en)
|
2007-10-19 |
2009-04-23 |
Abbott Laboratories |
Immunoassays and kits for the detection of ngal
|
|
KR20110013409A
(ko)
*
|
2008-05-23 |
2011-02-09 |
삼성전자주식회사 |
항체-펩티드 융합 상승체
|
|
JP5711118B2
(ja)
|
2008-06-24 |
2015-04-30 |
テクニッシュ ウニヴェルジテート ミュンヘン |
所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン
|
|
US8268314B2
(en)
*
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
|
US8133979B2
(en)
|
2008-12-16 |
2012-03-13 |
Hoffmann-La Roche Inc. |
Antibodies against human angiopoietin 2
|
|
WO2010111625A1
(en)
*
|
2009-03-27 |
2010-09-30 |
Zymogenetics, Inc. |
Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
|
|
BR112012013662B1
(pt)
*
|
2009-12-07 |
2022-08-02 |
Pieris Pharmaceuticals Gmbh |
Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
|
|
TWI426920B
(zh)
*
|
2010-03-26 |
2014-02-21 |
Hoffmann La Roche |
雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
|
|
NZ606584A
(en)
|
2010-08-16 |
2014-10-31 |
Pieris Ag |
Binding proteins for hepcidin
|
|
US9260492B2
(en)
|
2010-11-15 |
2016-02-16 |
Pieris Ag |
Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)
|
|
LT3495387T
(lt)
*
|
2012-07-13 |
2021-11-25 |
Roche Glycart Ag |
Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
|
|
WO2014076321A1
(en)
|
2012-11-19 |
2014-05-22 |
Pieris Ag |
Novel specific-binding polypeptides and uses thereof
|
|
KR20210094669A
(ko)
*
|
2013-04-29 |
2021-07-29 |
에프. 호프만-라 로슈 아게 |
인간 fcrn-결합 변형된 항체 및 사용 방법
|
|
EP3094650A2
(en)
*
|
2014-01-13 |
2016-11-23 |
Pieris Pharmaceuticals GmbH |
Multi-specific polypeptide useful for localized tumor immunomodulation
|
|
SG11201609274SA
(en)
*
|
2014-05-22 |
2016-12-29 |
Pieris Pharmaceuticals Gmbh |
Novel specific-binding polypeptides and uses thereof
|
|
AR103477A1
(es)
*
|
2015-01-28 |
2017-05-10 |
Lilly Co Eli |
Compuestos de vegfa / ang2
|
|
JP6839087B2
(ja)
*
|
2015-01-28 |
2021-03-03 |
ピエリス ファーマシューティカルズ ゲーエムベーハー |
血管新生に特異的な新規のタンパク質
|
|
TN2017000348A1
(en)
|
2015-02-18 |
2019-01-16 |
Sanofi Sa |
Novel proteins specific for pyoverdine and pyochelin
|
|
KR102734408B1
(ko)
|
2015-05-04 |
2024-11-27 |
피어이스 파마슈티컬즈 게엠베하 |
Cd137에 특이적인 신규한 단백질
|
|
AU2016262838B2
(en)
|
2015-05-18 |
2020-10-08 |
Pieris Pharmaceuticals Gmbh |
Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
|